IP Library Granted Patent US 9,271,992
Granted Patent B2
US 9,271,992 · App. 12/696,250 · Granted Mar 1, 2016

Method for alleviating pain using sphingosine-1-phosphate and related compounds, and assays for identifying such compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,271,992
App. No.
12/696,250
Granted
Mar 1, 2016
Kind
B2
Abstract

Methods for alleviating pain comprising administering to a subject sphingosine-1-phosphate, functional fragments and derivatives thereof, and other compounds, and assays for identifying such compounds.

Claims (21)

1. A method of alleviating pain associated with nociceptive processing or sensitization in the spinal cord and dorsal root ganglia, the method comprising administering to a subject experiencing pain a compound that activates a sphingosine-1-phosphate receptor in the spinal cord or dorsal root ganglia or enhances PAM (protein associated with Myc) activity in the spinal cord or dorsal root ganglia, wherein the compound is sphingosine-1-phosphate or a salt thereof or FTY 720 or a salt thereof, thereby alleviating pain associated with nociceptive processing or sensitization in the spinal cord and dorsal root ganglia in the subject.

2. The method of claim 1 , wherein the compound is administered intrathecally.

3. The method of claim 1 , wherein the compound is administered intravenously.

4. The method of claim 1 , wherein the compound is administered orally.

5. The method of claim 1 , wherein the subject is a mammal.

6. The method of claim 5 , wherein the mammal is a human.

7. The method of claim 1 , wherein the compound is sphingosine-1-phosphate or a salt thereof.

8. The method of claim 7 , wherein the compound is administered intrathecally.

9. The method of claim 7 , wherein the compound is administered intravenously.

10. The method of claim 7 , wherein the compound is administered orally.

11. The method of claim 7 , wherein the subject is a mammal.

12. The method of claim 11 , wherein the mammal is a human.

13. The method of claim 1 , wherein the compound is FTY 720 or a salt thereof.

14. The method of claim 13 , wherein the compound is administered intrathecally.

15. The method of claim 13 , wherein the compound is administered intravenously.

16. The method of claim 13 , wherein the compound is administered orally.

17. The method of claim 13 , wherein the subject is a mammal.

18. The method of claim 17 , wherein the mammal is a human.

19. The method of claim 1 , wherein the pain is nociceptive pain.

20. The method of claim 19 , wherein the nociceptive pain is chronic nociceptive pain.

21. The method of claim 19 , wherein the nociceptive pain is acute nociceptive pain.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2015
From: SCHOLICH, KLAUS, DR; GEISSLINGER, GERD, DR
To: FRAUNHOFER-GESELLESCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
Reel/Frame 036347/0838 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2015
From: SANOFI-AVENTIS DEUTSCHLAND GMBH
To: SCHOLICH, KLAUS, DR; GEISSLINGER, GERD, DR
Reel/Frame 034863/0832 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2010
From: MICHAELIS, MARTIN; GEISSLINGER, GERD; SCHOLICH, KLAUS
To: AVENTIS PHARMA DEUTSCHLAND GMBH
Reel/Frame 025409/0760 →
CHANGE OF NAME Recorded Nov 19, 2010
From: AVENTIS PHARMA DEUTSCHLAND GMBH
To: SANOFI-AVENTIS DEUTSCHLAND GMBH
Reel/Frame 025409/0795 →